Insilco molecular docking study of Dihydroisoquinolinium Derivatives as DPP IV Inhibitors in Type II Diabetes Mellitus

With the spread of western lifestyles, the occurrence of diabetes in the world’s population is rising. Diabetes is a complex metabolic endocrine disorder that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. It is classified into two basic forms Type I and Type II diabetes. A major goal for the treatment of type II diabetes is the enhancement of insulin secretion by pancreatic islet b-cells.